Research Program - Molecular Oncology
Research Program - Molecular Oncology
批准号:
10400659
负责人:
Gary M. Kupfer
金额:
$6.91万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-08-15 至 2024-04-30
关键词:
Antineoplastic AgentsAreaBasic ScienceBiologicalBiological MarkersCancer CenterCancer Center Support GrantCancer ControlCatchment AreaCellsChromosomesClinicClinical TrialsCollaborationsCommunitiesComplexComprehensive Cancer CenterCritical PathwaysDNADevelopmentDimensionsDirect CostsDiseaseDoctor of PhilosophyETS Family ProteinEWS-FLI1 fusion proteinEnvironmentEventFundingFutureGenomicsGoalsGrantGrowthHealthHomeIncidenceInstitutionInvestigational TherapiesInvestmentsJournalsKnowledgeLeadLiverLymphomaMaintenanceMalignant - descriptorMalignant NeoplasmsMeridiansMetabolismMissionModelingMolecularMusNCI Center for Cancer ResearchNational Cancer InstituteNeoplasm MetastasisNormal CellPancreatic Ductal AdenocarcinomaPaperPatient CarePatientsPeer ReviewPhasePhase I Clinical TrialsPhenotypePredispositionProcessProductivityPropertyPublicationsPublishingResearchResearch PersonnelResearch Project GrantsResource SharingTechnical ExpertiseTechnologyTherapeuticToxic effectTranslational ResearchUniversitiesWashingtonWorkZebrafishbasecancer cellcancer preventionepigenomicsinhibitorinsightmalignant breast neoplasmmembermetabolomicsmolecular oncologynovelnovel strategiesoncology programpredictive markerprogramsprotein protein interactionrecruitstem cell biologystem-like cellsuccesstherapeutic targettranscription factor
中文摘要
摘要
乔治城隆巴迪综合癌症中心(LCCC)分子肿瘤学项目(MO)
汇集了研究人员,他们的使命是识别和验证对人类免疫系统至关重要的分子途径。
癌症的发生、发展、维持和转移。MO的总体目标是了解
并为癌症易感性、起始和进展的复杂过程开发生物标志物,
鉴定新的靶点以及新的和重新利用的抗癌剂,
对正常细胞的毒性。为了完成这一使命和目标,MO成员在以下条件下进行研究:
两个目标:1)定义和利用启动和维持癌症的独特基因组和表观基因组事件
生长和2)确定干细胞样表型的生物学机制,改变
代谢和癌细胞的转移扩散。A.反映目标1进展的重大进展
Yi发现雅普调节胰腺导管腺癌的免疫抑制环境
(PDAC)。对于目标2,Chung发现茶酚酮E治疗显著降低了小鼠中的γ-OHPdG水平。
Xpa-/-小鼠的肝脏DNA,将这些小鼠的HCC发病率从对照组的100%降低至14%。的
LCCC联盟由乔治城隆巴迪综合癌症中心组成,总部设在
华盛顿,DC(LCCC-DC)和Hackensack Meridian Health的John Theurer癌症中心,
位于新泽西州哈肯萨克(LCCC-NJ)。因此,LCCC服务区由LCCC-DC定义,
LCCC 0 NJ集水区。由Jeffrey Toretsky博士和Benjamin Tycko博士领导,该计划
有21名成员和23名准成员,来自LCCC联盟机构的13个部门。在
本年度,MO成员得到768万美元(730万美元LCCC-DC,385,226美元LCCC-NJ)的支持,
研究补助金资金(年度直接费用),其中230万美元(192万美元LCCC-DC,385,226美元LCCC-NJ)是
同行评审和125.1万美元(在LCCC-DC)由国家癌症研究所(NCI)资助。MO是家
四项多人研究赠款金214篇癌症相关出版物证明了生产力,其中23篇
影响因子≥ 8的期刊。癌症和项目相关的出版物包括23%的跨-
方案内22%,方案间和方案内11%,36%
与其他癌症中心合作。办事处成员与其他三个地方协调中心的成员合作
研究计划(乳腺癌计划[BC],癌症预防和控制计划[CPC],
实验治疗计划[ET]),并使用所有九个共享资源。支持进行综合
专题研究,MO拥有重要的新技术专长,包括有条件地重新编程
细胞(CRC)、Zevatars和BiaCore 4000。
英文摘要
ABSTRACT
The Georgetown Lombardi Comprehensive Cancer Center (LCCC) Molecular Oncology Program (MO)
brings together investigators whose mission is to identify and validate molecular pathways critical to the
initiation, progression, maintenance and metastases of cancer. The overall goals of MO are to understand
and develop biomarkers for the complex processes of cancer susceptibility, initiation and progression, plus
identify novel targets and novel and repurposed anti-cancer agents that show promise because of reduced
toxicity against normal cells. To accomplish this mission and goals, MO members perform research under
two 2 aims: 1) Define and exploit unique genomic and epigenomic events that initiate and sustain cancer
growth and 2) determine the biological mechanisms that underlie stem cell-like phenotypes, altered
metabolism and the metastatic spread of cancer cells. A significant advances that reflects progress in Aim 1
by Yi found that Yap modulates the immunosuppressive environment in pancreatic ductal adenocarcinoma
(PDAC). For Aim 2, Chung identified theaphenon E treatment significantly decreased γ-OHPdG levels in the
liver DNA of Xpa-/- mice that reduced HCC incidence in these mice to 14% from 100% in the controls. The
LCCC Consortium is comprised of Georgetown Lombardi Comprehensive Cancer Center, based in
Washington, DC (LCCC-DC) and the John Theurer Cancer Center of Hackensack Meridian Health, based
in Hackensack, NJ (LCCC-NJ). Accordingly, the LCCC catchment area is defined by the LCCC-DC and
LCCC0NJ catchment areas. Led by Jeffrey Toretsky, MD and Benjamin Tycko, MD, PhD, the program
has 21 members and 23 associate members from 13 departments across LCCC Consortium institutions. In
the current year, MO members are supported by $7.68M ($7.3M LCCC-DC, $385,226 LCCC-NJ) in
research grant funding (annual direct costs) of which $2.3M ($1.92M LCCC-DC, $385,226 LCCC-NJ) is
peer reviewed and $1.251M (at LCCC-DC) is funded by the National Cancer Institute (NCI). MO is home to
four multi-investigator grants. Productivity is demonstrated by 214 cancer-related publications, 23 of which
were in journals with an impact factor ≥ 8. Cancer and program-related publications included 23% inter-
programmatic, 22% intra-programmatic, 11% inter- and intra-programmatic and 36% that involved
collaborations with another cancer center. MO members collaborate with members of the other three LCCC
Research Programs (Breast Cancer Program [BC], Cancer Prevention and Control Program [CPC], and
Experimental Therapeutics Program [ET]) and use all nine Shared Resources. To support integrated
thematic research, MO houses significant novel technical expertise, including conditionally reprogrammed
cells (CRCs), Zevatars, and a BiaCore 4000.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanistic Dissection of the Falconi Anemia Pathway of DNA Damage Response and Repair
-
批准号:9899099
-
项目类别:
-
资助金额:$37.18万
-
财政年份:2019
-
负责人:Gary M. Kupfer
-
依托单位:
Mechanistic Dissection of the BRCA1-SETX-dependent Pathway of R-loop Avoidance and Genome Maintenance
-
批准号:10537108
-
项目类别:
-
资助金额:$50.88万
-
财政年份:2013
-
负责人:Gary M. Kupfer
-
依托单位:
Mechanistic Dissection of the Fanconi Anemia Pathway of DNA Damage Response and R
-
批准号:8505689
-
项目类别:
-
资助金额:$34.52万
-
财政年份:2013
-
负责人:Gary M. Kupfer
-
依托单位:
Mechanistic Dissection of the Fanconi Anemia Pathway of DNA Damage Response and R
-
批准号:8641673
-
项目类别:
-
资助金额:$33.51万
-
财政年份:2013
-
负责人:Gary M. Kupfer
-
依托单位:
Mechanistic Dissection of the BRCA1-SETX-dependent Pathway of R-loop Avoidance and Genome Maintenance
-
批准号:10641022
-
项目类别:
-
资助金额:$48.52万
-
财政年份:2013
-
负责人:Gary M. Kupfer
-
依托单位:
Mechanistic Dissection of the Fanconi Anemia Pathway of DNA Damage Response and R
-
批准号:8826073
-
项目类别:
-
资助金额:$34.55万
-
财政年份:2013
-
负责人:Gary M. Kupfer
-
依托单位:
HTLV I Tax1 protein chemosensitization of p53 mutant tumors
-
批准号:8053781
-
项目类别:
-
资助金额:$20.95万
-
财政年份:2010
-
负责人:Gary M. Kupfer
-
依托单位:
HTLV I Tax1 protein chemosensitization of p53 mutant tumors
-
批准号:7872281
-
项目类别:
-
资助金额:$18.0万
-
财政年份:2010
-
负责人:Gary M. Kupfer
-
依托单位:
FANCD2 interaction with mismatch repair proteins and MCM2-7
-
批准号:8616392
-
项目类别:
-
资助金额:$48.66万
-
财政年份:2000
-
负责人:Gary M. Kupfer
-
依托单位:
The Fanconi Anemia Core and D2 Complexes
-
批准号:7440298
-
项目类别:
-
资助金额:$36.71万
-
财政年份:2000
-
负责人:Gary M. Kupfer
-
依托单位:
FANCD2 interaction with mismatch repair proteins and MCM2-7
-
批准号:8231274
-
项目类别:
-
资助金额:$49.65万
-
财政年份:2000
-
负责人:Gary M. Kupfer
-
依托单位:
FANCD2 interaction with mismatch repair proteins and MCM2-7
-
批准号:8040202
-
项目类别:
-
资助金额:$49.65万
-
财政年份:2000
-
负责人:Gary M. Kupfer
-
依托单位:
FANCD2 interaction with mismatch repair proteins and MCM2-7
-
批准号:8438399
-
项目类别:
-
资助金额:$47.27万
-
财政年份:2000
-
负责人:Gary M. Kupfer
-
依托单位:
The Fanconi Anemia Core and D2 Complexes
-
批准号:7632267
-
项目类别:
-
资助金额:$39.23万
-
财政年份:2000
-
负责人:Gary M. Kupfer
-
依托单位:
国内基金
海外基金
层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
-
批准号:2021JJ40433
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2021
-
负责人:孙磊
-
依托单位:
寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
-
批准号:32001603
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:段真珍
-
依托单位:
AREA国际经济模型的移植.改进和应用
-
批准号:18870435
-
项目类别:面上项目
-
资助金额:2.0万元
-
批准年份:1988
-
负责人:史树中
-
依托单位: